Evidence map›Paper›PMID 41479562›Full record

ArticleActa naturae

mRNA-Based Personalized Cancer Vaccines: Opportunities, Challenges and Outcomes.

A A Ibragimova, A A Fedorov, K M Kirilenko, E L Choynzonov, E V Denisov, M R Patysheva

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta naturae. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

A A IbragimovaCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, 634009 Russia.
A A FedorovCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, 634009 Russia.
K M KirilenkoCenter for Systems Bioinformatics, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, 634050 Russia.
E L ChoynzonovCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, 634009 Russia.
E V DenisovCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, 634009 Russia.
M R PatyshevaCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, 634009 Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

mRNA-based cancer vaccines represent an innovative approach to cancer treatment. Cancer mRNA vaccines are structurally based on specific tumor antigens, a technique which enables the patient's immune system to become activated against cancer cells. Clinical trials of mRNA vaccines against various types of tumors, including melanoma, lung cancer, pancreatic carcinoma, breast cancer and others, are currently underway. Because of their favorable safety profile and adaptability, these therapeutics hold considerable promise in efforts to enhance cancer treatment efficacy and prolong patient life. This review outlines steps in the development of manufacturing technologies for mRNA-based therapeutics, describes the algorithm used to design personalized anti-tumor mRNA vaccines, discusses their practical implementation, and summarizes current clinical trials in cancer immunotherapy.

Indexed as

cancerclinical trialsimmunotherapyliposomesmRNA vaccineneoantigens

Identifiers

PMID41479562
PMCPMC12755870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.